Podcast
MSL Talk: Tom Caravela, Stephanie Otis
What is Your Value?: Defining and Driving MSL Value Demonstration
Summary
In this episode, Tom Caravela welcomes Cherie Hyder to discuss the critical topic of MSLs demonstrating VALUE. The conversation delves into defining value and effectively showcasing it to key stakeholders, including KOLs, with an emphasis on patient-centricity. The role of internal collaboration in enhancing value is examined, along with methods for measuring and communicating this value within organizations. They explore how tools and technology can aid MSLs in enhancing their perceived value and address common challenges faced in value demonstration. Strategies for MSLs who feel undervalued are shared, concluding with Cherie's final advice and closing remarks.
Key Points
- Emphasizing both quantitative and qualitative metrics is essential for MSLs to effectively demonstrate their value within the organization.
- Maintaining patient-centricity by understanding and communicating patient experiences and needs can significantly enhance the impact of an MSL's work.
- Continuous self-investment in skills and capabilities is crucial for MSLs to adapt to changes and remain valuable in a rapidly evolving medical landscape.
MSLs value demonstration, patient-centricity, internal collaboration, tools and technology for MSLs, strategies for undervalued MSLs
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Stephanie Otis
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Podcast
Michael Pietrack
Hiring Managers Beware: Reverse Rejection Explained!
Article
Jamie Riley
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Forbes Books Press Release Official